These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 27828640

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Alemtuzumab as first- and second-line treatment in patients with Sézary syndrome-The experience of a tertiary centre.
    Nogueira M, Lau C, Teixeira MDA, Peixeiro R, Cabral R, Fernandes I.
    J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):e86-e88. PubMed ID: 37595960
    [No Abstract] [Full Text] [Related]

  • 25. Subcutaneous alemtuzumab for Sézary Syndrome in the very elderly.
    Alinari L, Geskin L, Grady T, Baiocchi RA, Bechtel MA, Porcu P.
    Leuk Res; 2008 Aug; 32(8):1299-303. PubMed ID: 18096224
    [Abstract] [Full Text] [Related]

  • 26. [Persistent Effects of Mogamulizumab on Peripheral Blood Lesions after Treatment Completion in a Patient with Refractory Sézary Syndrome-A Case Report].
    Manabe M, Endo H, Inano N, Hagiwara Y, Nanno S, Koh KR.
    Gan To Kagaku Ryoho; 2024 Aug; 51(8):833-835. PubMed ID: 39191715
    [Abstract] [Full Text] [Related]

  • 27. Sézary syndrome managed with histone deacetylase inhibitor followed by anti-CCR4 monoclonal antibody.
    Numata T, Nagatani T, Shirai K, Maeda T, Mae K, Nakasu M, Saito M, Usuda T, Tsuboi R, Okubo Y.
    Clin Exp Dermatol; 2018 Apr; 43(3):281-285. PubMed ID: 29327377
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Fatal adenoviral and enteroviral infections and an Epstein-Barr virus positive large B-cell lymphoma after alemtuzumab treatment in a patient with refractory Sézary syndrome.
    Roch N, Salameire D, Gressin R, Morand P, Epaulard O, Pavese P, Brion JP, Stahl JP.
    Scand J Infect Dis; 2008 Apr; 40(4):343-6. PubMed ID: 17934981
    [Abstract] [Full Text] [Related]

  • 30. Successful treatment of refractory Sezary syndrome by anti-PD-1 antibody (nivolumab).
    Shen K, Liu Y, Cao X, Zhou D, Li J.
    Ann Hematol; 2017 Apr; 96(4):687-688. PubMed ID: 28120019
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The emergence of Sézary cells during the treatment of cutaneous T-cell lymphoma.
    Sato M, Ishikawa O, Miyachi Y.
    Br J Dermatol; 1995 Nov; 133(5):810-3. PubMed ID: 8555042
    [Abstract] [Full Text] [Related]

  • 33. Serum chemokine levels differentially regulated by vorinostat in a Sézary syndrome patient.
    Miyagaki T, Sugaya M, Oka T, Fujita H, Sato S.
    Br J Dermatol; 2015 Aug; 173(2):620-2. PubMed ID: 25640919
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas.
    de Masson A, Guitera P, Brice P, Moulonguet I, Mouly F, Bouaziz JD, Battistella M, Madelaine I, Roux J, Ram-Wolff C, Cayuela JM, Bachelez H, Bensussan A, Michel L, Bagot M.
    Br J Dermatol; 2014 Mar; 170(3):720-4. PubMed ID: 24438061
    [Abstract] [Full Text] [Related]

  • 36. Mogamulizumab-induced vitiligo in patients with Sézary syndrome: three cases.
    Algarni AS, Ram-Wolff C, Bagot M, De Masson A.
    Eur J Dermatol; 2021 Apr 01; 31(2):213-216. PubMed ID: 33814357
    [Abstract] [Full Text] [Related]

  • 37. [The Sézary syndrome].
    Ferreira F, Correia TM, Callabro L, Andrade J.
    Acta Med Port; 1998 Dec 01; 11(12):1135-9. PubMed ID: 10192992
    [Abstract] [Full Text] [Related]

  • 38. Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study.
    Gorin NC, Isnard F, Garderet L, Ikhlef S, Corm S, Quesnel B, Legrand O, Cachanado M, Rousseau A, Laporte JP.
    Eur J Haematol; 2013 Oct 01; 91(4):315-21. PubMed ID: 23738686
    [Abstract] [Full Text] [Related]

  • 39. Sézary Syndrome Presenting With Renal Involvement.
    Wickenden K, Graham-Brown MPM, Veitch D, Dormer J, Bamford M, Graham-Brown RAC, Warwick G, Wagner S, Burton JO.
    Am J Kidney Dis; 2018 Dec 01; 72(6):890-894. PubMed ID: 29941220
    [Abstract] [Full Text] [Related]

  • 40. A case of refractory Sézary syndrome with large-cell transformation responsive to brentuximab vedotin.
    Corey K, Cook D, Bekker J, Mugnaini E, Lin JH.
    JAMA Dermatol; 2014 Feb 01; 150(2):210-2. PubMed ID: 24352253
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.